IOL Chemicals, known for its leadership in Ibuprofen, is expanding its product range by venturing into non-Ibuprofen APIs and increasing Paracetamol production. Despite a 10.9% revenue increase in Q3 FY26, the profit after tax (PAT) remained unchanged due to cost pressures and exceptional items. The company's growth is attributed to strong exports and new API developments.

IOL Chemicals, due to its recent price surge, is now deemed as having a high valuation relative to the industry standard, potentially making it less attractive compared to competitors in the sector. This shift in evaluation suggests a need for investors to reconsider their investment strategy regarding this company.